These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1784 related items for PubMed ID: 19107621

  • 1. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 2. Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.
    Søiland H, Janssen EA, Kørner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA.
    Breast Cancer Res Treat; 2009 Feb; 113(3):519-28. PubMed ID: 18330697
    [Abstract] [Full Text] [Related]

  • 3. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T.
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [Abstract] [Full Text] [Related]

  • 4. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 5. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.
    Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M.
    Clin Cancer Res; 2007 Apr 01; 13(7):1987-94. PubMed ID: 17404078
    [Abstract] [Full Text] [Related]

  • 6. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 7. Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen.
    Girault I, Lerebours F, Amarir S, Tozlu S, Tubiana-Hulin M, Lidereau R, Bièche I.
    Clin Cancer Res; 2003 Apr 20; 9(4):1259-66. PubMed ID: 12684393
    [Abstract] [Full Text] [Related]

  • 8. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.
    Cancer; 2008 Apr 01; 112(7):1437-44. PubMed ID: 18286526
    [Abstract] [Full Text] [Related]

  • 9. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
    Holm C, Rayala S, Jirström K, Stål O, Kumar R, Landberg G.
    J Natl Cancer Inst; 2006 May 17; 98(10):671-80. PubMed ID: 16705121
    [Abstract] [Full Text] [Related]

  • 10. Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy.
    Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, Austrian Breast and Colorectal Cancer Study Group.
    Clin Cancer Res; 2009 Sep 15; 15(18):5888-94. PubMed ID: 19723645
    [Abstract] [Full Text] [Related]

  • 11. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.
    J Natl Cancer Inst; 2008 Oct 01; 100(19):1380-8. PubMed ID: 18812550
    [Abstract] [Full Text] [Related]

  • 12. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
    Debled M, MacGrogan G, Brouste V, Mathoulin-Pelissier S, Durand M, Mauriac L.
    Cancer; 2007 Jun 01; 109(11):2197-204. PubMed ID: 17450590
    [Abstract] [Full Text] [Related]

  • 13. Phospho-serine-118 estrogen receptor-alpha expression is associated with better disease outcome in women treated with tamoxifen.
    Murphy LC, Niu Y, Snell L, Watson P.
    Clin Cancer Res; 2004 Sep 01; 10(17):5902-6. PubMed ID: 15355923
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D, Bieche I, Aumas C, Esselin S, Bouquet C, Vacher S, Lazennec G, Perricaudet M, Kuttenn F, Lidereau R, de Roux N.
    Endocr Relat Cancer; 2007 Sep 01; 14(3):691-702. PubMed ID: 17914099
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.